Abraxane and Transferrin decreased - a phase IV clinical study of FDA data

Summary:

Transferrin decreased is reported as a side effect among people who take Abraxane (paclitaxel), especially for people who are male, 60+ old, also take Apixaban, and have Anaplastic thyroid cancer.

The phase IV clinical study analyzes which people have Transferrin decreased when taking Abraxane. It is created by eHealthMe based on reports of 19,123 people who have side effects when taking Abraxane from the FDA, and is updated regularly.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

What is Transferrin decreased?

Transferrin decreased is found to be associated with 69 drugs and 96 conditions by eHealthMe. Check the latest studies of Transferrin decreased.

On Jul, 14, 2026

19,123 people reported to have side effects when taking Abraxane.
Among them, 14 people (0.07%) have Transferrin decreased.

Could Abraxane cause Transferrin decreased?

Among these 14 people:

What is the gender of people who have Transferrin decreased when taking Abraxane? *

female: 0.0 %
male: 100 %

What is the age of people who have Transferrin decreased when taking Abraxane? *

What are other drugs people take besides Abraxane? *

What are other side effects people have besides Transferrin decreased? *

Hyperglycemia (high blood sugar): 14 people, 100.00%
Blood Iron Decreased: 14 people, 100.00%
Hoarseness Or Changing Voice: 14 people, 100.00%
High Blood Pressure: 14 people, 100.00%
Itching: 14 people, 100.00%
Gastric Haemorrhage (bleeding stomach): 14 people, 100.00%
Fatigue (feeling of tiredness): 14 people, 100.00%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 14 people, 100.00%
Dry Skin: 14 people, 100.00%
Diarrhea: 14 people, 100.00%

What are the existing conditions these people have? *

Thrombosis (formation of a blood clot inside a blood vessel): 11 people, 78.57%
Pain: 11 people, 78.57%
Oedema (fluid collection in tissue): 11 people, 78.57%
Jugular Vein Thrombosis (clot in jugular vein): 11 people, 78.57%
Anaplastic Thyroid Cancer (thyroid cancer which has a very poor prognosis): 11 people, 78.57%
Respiratory Disorder (respiratory disease): 8 people, 57.14%
Thyroid Cancer: 4 people, 28.57%
Dyspnea (difficult or laboured breathing): 4 people, 28.57%
Gastritis (inflammation of stomach): 3 people, 21.43%
Electrolyte Imbalance: 3 people, 21.43%

* Approximation only. Some reports may have incomplete information.

Do you take Abraxane and have Transferrin decreased?

- Check whether Transferrin decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abraxane:

Abraxane (19,196 reports)

Browse all side effects of Abraxane:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transferrin decreased:

Transferrin decreased (69 drugs)

Browse all the conditions that are associated with Transferrin decreased:

Transferrin decreased (96 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paclitaxel (the active ingredients of Abraxane) and Abraxane (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.